Ambu Q3 2024/25 expects front-loaded revenue growth due to strong Q1 order-phasing in Pulmonology and Anaesthesia & Patient Monitoring. H1 organic revenue growth at 15.4%, with a 12-month rolling growth of 14.1%. Endoscopy Solutions posted 16.7% growth for H1, driven by 4 new products. Anaesthesia & Patient Monitoring saw a 13.6% growth in H1, aided by price increases. EBIT margin for H1 at 15.2%, with full-year guidance adjusted to 12-14%. Free cash flow remains stable at DKK +500m for 2024/25.
Hurtige nyheder er stadig i beta-fasen, og fejl kan derfor forekomme.
